Response to tolvaptan and its effect on prognosis in cirrhotic patients with ascites-Reference-Cited by-同舟云学术

Response to tolvaptan and its effect on prognosis in cirrhotic patients with ascites

Published:2016-11-15 Issue:9 Volume:47 Page:835-844
ISSN:1386-6346
Container-title:Hepatology Research
language:en
Short-container-title:Hepatol Res

Author:

Kogiso Tomomi¹,Yamamoto Kuniko¹,Kobayashi Mutsuki¹,Ikarashi Yuichi¹,Kodama Kazuhisa¹,Taniai Makiko¹,Torii Nobuyuki¹,Hashimoto Etsuko¹,Tokushige Katsutoshi¹

Affiliation:

1. Institute of Gastroenterology, Department of Internal Medicine; Tokyo Women's Medical University; Tokyo Japan

Publisher

Wiley

Subject

Infectious Diseases,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/hepr.12822/fullpdf

Reference42 articles.

1. Natural history of patients hospitalized for management of cirrhotic ascites;Planas;Clin Gastroenterol Hepatol,2006

2. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis;Schrier;Hepatology,1988

3. Update on new aspects of the renin-angiotensin system in liver disease: clinical implications and new therapeutic options;Grace;Clin Sci (Lond),2012

4. Complications of diuretic therapy in hepatic cirrhosis;Sherlock;Lancet,1966

5. Randomized comparative study of efficacy of furosemide versus spironolactone in nonazotemic cirrhosis with ascites. Relationship between the diuretic response and the activity of the renin-aldosterone system;Pérez-Ayuso;Gastroenterology,1983

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neutrophil gelatinase-associated lipocalin predicts the efficacy of tolvaptan for ascites in patients with liver cirrhosis;Journal of Gastroenterology;2023-04-27

2. The Effects of SGLT2 Inhibitors on Liver Cirrhosis Patients with Refractory Ascites: A Literature Review;Journal of Clinical Medicine;2023-03-14

3. Cisterna chyli as an optimal marker of tolvaptan response in severe cirrhotic ascites;Scientific Reports;2022-05-17

4. Risk and protective factors of acute kidney injury in decompensated cirrhotic patients with ascites on tolvaptan;JGH Open;2021-11

5. A genome‐wide association study identifying SVEP1 variant as a predictor of response to tolvaptan for cirrhotic ascites;Liver International;2021-08-08